Influence of 5-HT3 receptor subunit genes HTR3A, HTR3B, HTR3C, HTR3D and HTR3E on treatment response to antipsychotics in schizophrenia

Pharmacogenetics and Genomics

Volumn 19, Issue 11, 2009, Pages 843-851

  Schuhmacher, Anna ^a   Mössner, Rainald ^a   Quednow, Boris B ^a,e   Kühn, Kai Uwe ^a   Wagner, Michael ^a   Cvetanovska, Gabriela ^a   Rujescu, Dan ^b   Zill, Peter ^b   Möller, Hans Jürgen ^b   Rietschel, Marcella ^c   Franke, Petra ^d   Wölwer, Wolfgang ^d   Gaebel, Wolfgang ^d   Maier, Wolfgang ^a  

^a UNIVERSITY OF BONN   (Germany)

^b UNIVERSITY OF MUNICH   (Germany)

^c CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^d HEINRICH HEINE UNIVERSITY   (Germany)

^e UNIVERSITY HOSPITAL OF PSYCHIATRY   (Switzerland)

Author keywords

5 HT3; Atypical antipsychotics; HTR3E; Negative symptoms; PANSS; Positive symptoms; Response; Schizophrenia; Serotonin

Indexed keywords

AMISULPRIDE; ARIPIPRAZOLE; ATYPICAL ANTIPSYCHOTIC AGENT; BENZODIAZEPINE DERIVATIVE; BIFEPRUNOX; CLOZAPINE; HALOPERIDOL; ILOPERIDONE; NEUROLEPTIC AGENT; OLANZAPINE; QUETIAPINE; RISPERIDONE; SEROTONIN 3 RECEPTOR; SEROTONIN 3A RECEPTOR; SEROTONIN 3B RECEPTOR; SEROTONIN 3C RECEPTOR; SEROTONIN 3D RECEPTOR; SEROTONIN 3E RECEPTOR; UNCLASSIFIED DRUG; ZIPRASIDONE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; FEMALE; GENE FREQUENCY; GENOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEGATIVE SYNDROME; POSITIVE AND NEGATIVE SYNDROME SCALE; POSITIVE SYNDROME; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN VARIANT; RANDOMIZED CONTROLLED TRIAL; SCHIZOPHRENIA; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT RESPONSE;

ADULT; AMINO ACIDS; ANTIPSYCHOTIC AGENTS; DEMOGRAPHY; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; POLYMORPHISM, SINGLE NUCLEOTIDE; PROTEIN SUBUNITS; RECEPTORS, SEROTONIN, 5-HT3; SCHIZOPHRENIA; TIME FACTORS; TREATMENT OUTCOME;

EID: 74049132250     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e3283313296     Document Type: Article

References (41)

1. Mossner R, Schuhmacher A, Kuhn KU, Cvetanovska G, Rujescu D, Zill P, et al. Functional serotonin 1A receptor variant influences treatment response to atypical antipsychotics in schizophrenia. Pharmacogenet Genomics 2009; 19: 91-94.
2. Arranz MJ, de Leon J. Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol Psychiatry 2007; 12: 707-747.
3. Wang L, Fang C, Zhang A, Du J, Yu L, Ma J, et al. The -1019 C/G polymorphism of the 5-HT(1)A receptor gene is associated with negative symptom response to risperidone treatment in schizophrenia patients. J Psychopharmacol 2008; 22: 904-909.
4. Reynolds GP, Arranz B, Templeman LA, Fertuzinhos S, San L. Effect of 5-HT1A receptor gene polymorphism on negative and depressive symptom response to antipsychotic treatment of drug-naive psychotic patients. Am J Psychiatry 2006; 163: 1826-1829. (Pubitemid 44522494)
5. Lane HY, Chang YC, Chiu CC, Chen ML, Hsieh MH, Chang WH. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene. Am J Psychiatry 2002; 159: 1593-1595. (Pubitemid 35006743)
6. Arranz M, Collier D, Sodhi M, Ball D, Roberts G, Price J, et al. Association between clozapine response and allelic variation in 5-HT2A receptor gene. Lancet 1995; 346: 281-282.
7. Arranz MJ, Munro J, Sham P, Kirov G, Murray RM, Collier DA, et al. Meta-analysis of studies on genetic variation in 5-HT2A receptors and clozapine response. Schizophr Res 1998; 32: 93-99. (Pubitemid 28364714)
8. Arranz MJ, Collier DA, Munro J, Sham P, Kirov G, Sodhi M, et al. Analysis of a structural polymorphism in the 5-HT2A receptor and clinical response to clozapine. Neurosci Lett 1996; 217: 177-178. (Pubitemid 26358831)
9. Masellis M, Basile V, Meltzer HY, Lieberman JA, Sevy S, Macciardi FM, et al. Serotonin subtype 2 receptor genes and clinical response to clozapine in schizophrenia patients. Neuropsychopharmacology 1998; 19: 123-132. (Pubitemid 28288438)
10. Levkovitz Y, Arnest G, Mendlovic S, Treves I, Fennig S. The effect of ondansetron on memory in schizophrenic patients. Brain Res Bull 2005; 65: 291-295. (Pubitemid 41057797)
11. Adler LE, Cawthra EM, Donovan KA, Harris JG, Nagamoto HT, Olincy A, et al. Improved p50 auditory gating with ondansetron in medicated schizophrenia patients. Am J Psychiatry 2005; 162: 386-388. (Pubitemid 40216223)
12. Koike K, Hashimoto K, Takal N, Shimizu E, Komatsu N, Watanabe H, et al. Tropisetron improves deficits in auditory P50 suppression in schizophrenia. Schizophr Res 2005; 76: 67-72. (Pubitemid 40824561)
13. Thompson AJ, Lummis SC. The 5-HT3 receptor as a therapeutic target. Expert Opin Ther Targets 2007; 11: 527-540.
14. Barnes NM, Sharp T. A review of central 5-HT receptors and their function. Neuropharmacology 1999; 38: 1083-1152. (Pubitemid 29292403)
15. Niesler B, Walstab J, Combrink S, Moller D, Kapeller J, Rietdorf J, et al. Characterization of the novel human serotonin receptor subunits 5-HT3C, 5-HT3D and 5-HT3E. Mol Pharmacol 2007; 72: 8-17.
16. Niesler B, Kapeller J, Hammer C, Rappold G. Serotonin type 3 receptor genes: HTR3A, B, C, D, E. Pharmacogenomics 2008; 9: 501-504. (Pubitemid 351803911)
17. Davies PA, Pistis M, Hanna MC, Peters JA, Lambert JJ, Hales TG, et al. The 5-HT3B subunit is a major determinant of serotonin-receptor function. Nature 1999; 397: 359-363. (Pubitemid 29061650)
18. Niesler B, Frank B, Kapeller J, Rappold GA. Cloning, physical mapping and expression analysis of the human 5-HT3 serotonin receptor-like genes HTR3C, HTR3D and HTR3E. Gene 2003; 310: 101-111. (Pubitemid 36703304)
19. Barnes NM, Hales TG, Lummis SC, Peters JA. The 5-HT3 receptor - the relationship between structure and function. Neuropharmacology 2009; 56: 273-284.
20. Wolwer W, Buchkremer G, Hafner H, Klosterkotter J, Maier W, Moller HJ, et al. German research network on schizophrenia - bridging the gap between research and care. Eur Arch Psychiatry Clin Neurosci 2003; 253: 321-329. (Pubitemid 38075974)
21. Gaebel W, Moller HJ, Buchkremer G, Ohmann C, Riesbeck M, Wolwer W, et al. Pharmacological long-term treatment strategies in first episode schizophrenia-study design and preliminary results of an ongoing RCT within the German Research Network on Schizophrenia. Eur Arch Psychiatry Clin Neurosa 2004; 254: 129-140. (Pubitemid 39304480)
22. Moller HJ, Riedel M, Jager M, Wickelmaier F, Maier W, Kuhn KU, et al. Short-term treatment with risperidone or haloperidol in first-episode schizophrenia: 8-week results of a randomized controlled trial within the German Research Network on Schizophrenia. Int J Neuropsychopharmacol 2008; 11: 985-997.
23. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276. (Pubitemid 18039085)
24. Erdfelder E, Faul F, Buchner A. GPOWER: a general power analysis program. Behav Res Methods Instrum Comput 1996; 28: 1-11. (Pubitemid 126416697)
25. Niesler B, Flohr T, Nothen MM, Fischer C, Rietschel M, Franzek E, et al. Association between the 5' UTR variant C178 T of the serotonin receptor gene HTR3A and bipolar affective disorder. Pharmacogenetics 2001; 11: 471-475. (Pubitemid 32778225)
26. Hashimoto T, Kitamura N, Kajimoto Y, Shirai Y, Shirakawa O, Mita T, et al. Differential changes in serotonin 5-HT1A and 5-HT2 receptor binding in patients with chronic schizophrenia. Psychopharmacology (Berl) 1993; 112 (1 Suppl): S35-39.
27. Ikeda M, Yamanouchi Y, Kinoshita Y, Kitajima T, Yoshimura R, Hashimoto S, et al. Variants of dopamine and serotonin candidate genes as predictors of response to risperidone treatment in first-episode schizophrenia. Pharmacogenomics 2008; 9: 1437-1443.
28. Meltzer HY. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology 1999; 21 (2 Suppl): 106S-115S.
29. De Deurwaerdere P, Stinus L, Spampinato U. Opposite change of in vivo dopamine release in the rat nucleus accumbens and striatum that follows electrical stimulation of dorsal raphe nucleus: role of 5-HT3 receptors. J Neurosci 1998; 18: 6528-6538. (Pubitemid 28373254)
30. Blandina P, Goldfarb J, Green JP. Activation of a 5-HT3 receptor releases dopamine from rat striatal slice. Eur J Pharmacol 1988; 155: 349-350. (Pubitemid 18253633)
31. Costall B, Domeney AM, Naylor RJ, Tyers MB. Effects of the 5-HT3 receptor antagonist, GR38032F, on raised dopaminergic activity in the mesolimbic system of the rat and marmoset brain. Br J Pharmacol 1987; 92: 881-894. (Pubitemid 18014940)
32. Rammes G, Eisensamer B, Ferrari U, Shapa M, Gimpl G, Gilling K, et al. Antipsychotic drugs antagonize human serotonin type 3 receptor currents in a noncompetitive manner. Mol Psychiatry 2004; 9: 846-858, 818. (Pubitemid 39273531)
33. Hermann B, Wetzel CH, Pestel E, Zieglgansberger W, Holsboer F, Rupprecht R. Functional antagonistic properties of clozapine at the 5-HT3 receptor. Biochem Biophys Res Commun 1996; 225: 957-960. (Pubitemid 26319210)
34. Lummis SC, Baker J. Radioligand binding and photoaffinity labelling studies show a direct interaction of phenothiazines at 5-HT3 receptors. Neuropharmacology 1997; 36: 665-670. (Pubitemid 27272112)
35. Watling KJ, Beer MS, Stanton JA, Newberry NR. Interaction of the atypical neuroleptic clozapine with 5-HT3 receptors in the cerebral cortex and superior cervicai ganglion of the rat. Eur J Pharmacol 1990; 182: 465-472.
36. DeQuardo JR. Pharmacologic treatment of first-episode schizophrenia: early intervention is key to outcome. J Clin Psychiatry 1998; 59 (Suppl 19): 9-17.
37. Buckley PE, Evans D. First-episode schizophrenia. A window of opportunity for optimizing care and outcomes. Postgrad Med 2006; Spec No:5-19.
38. Johnsen E, Jorgensen HA. Effectiveness of second generation antipsychotics: a systematic review of randomized trials. BMC Psychiatry 2008; 8: 31. (Pubitemid 351712549)
39. Iidaka T, Ozaki N, Matsumoto A, Nogawa J, Kinoshita Y, Suzuki T, et al. A variant C178 T in the regulatory region of the serotonin receptor gene HTR3A modulates neural activation in the human amygdala. J Neurosci 2005; 25: 6460-6466. (Pubitemid 40965551)
40. Gutiérrez B, Arranz MJ, Huezo-Diaz P, Dempster D, Matthlasson P, Travis M, et al. Novel mutations in 5-HT3A and 5-HT3B receptor genes not associated with clozapine response. Schizophr Res 2002; 58: 93-97.
41. Krzywkowski K, Davies PA, Feinberg-Zadek PL, Brauner-Osborne H, Jensen AA. High-frequency HTR3B variant associated with major depression dramatically augments the signaling of the human 5-HT3AB receptor. Proc Natl Acad Sci U S A 2008; 105: 722-727. (Pubitemid 351171775)